Searched for
IPO PLANS BIOCON
The alchemist of Bengaluru: Kiran Mazumdar-Shaw began from a garageKiran Mazumdar-Shaw has named her niece Claire Mazumdar as successor, setting up a gradual leadership transition at Biocon. A pioneer who b...- Biocon to make Biocon Biologics a wholly owned subsidiaryBiocon is set to fully integrate its biosimilar arm, Biocon Biologics. This move will make Biocon Biologics a wholly owned subsidiary. Bioc...
- Biocon plans ₹4,500-cr QIP to raise stake in Biologics unit: Kiran ShawBiocon is planning a ₹4,500 crore fundraise to increase promoter stake in Biocon Biologics and convert structured venture debt into equity,...
- Biocon plans IPO for biosimilars business by March 2026Biocon plans to list its biosimilars business by March 2026 and aims for a double-digit market share in the U.S. for five new biosimilars l...
- Biocon to use debt, equity and IPO to buy Viatris biosimilars biz: Kiran Mazumdar Shaw“It will be a mix of debt, equity and of course IPO. It is going to be a very interesting business opportunity and a very comfortable aspec...
- Biocon Biologics to file for IPO within next 2 years: Kiran Mazumdar-Shaw"And obviously, we expect the IPO to be at a very, very attractive level. So if you look at it, it's going to hugely create value for share...
- Biocon Biologics to expand to Latin America, Africa and Asia“We are investing thoughtfully to expand the global footprint step by step across the world. We have opened regional offices across Latin A...
- True North buys into Biocon Biologics, deal values firm at around $3.5 billionTrue North has acquired about 3 per cent of Biocon Biologics India Ltd (BBIL), a wholly owned subsidiary of Biocon, for $100 million, valui...
- Syngene IPO over-subscribed on second dayThe IPO got bids for 1,60,79,700 shares against 1,60,00,000 shares on offer, resulting in a subscription of 1.01 (rpt) 1.01 times, accordin...
- Management commentary, capex outlook hold the key for Biocon: Mayuresh JoshiIf you look at how the business model has evolved for Biocon, Syngene is the one which is driving the overall profitability for the company...
- Biocon sets Syngene IPO price band at Rs 240-250Biocon plans to raise Rs 550 crore by diluting 11% stake in Syngene through the Initial Public Offer. The proceeds will mostly go into fund...
- Syngene IPO opens July 27; price band at Rs 240-250; Biocon shares end in redBiocon's subsidiary Syngene has set the price band for its forthcoming IPO at Rs 240-250 per share that will open on July 27.
- Plan to list Syngene in August, use IPO proceeds for R&D: Kiran Mazumdar-ShawSyngene International, present in the contract services business, had filed its draft red herring prospectus (DRHP) with Sebi .
- Biocon shares end higher as arm Syngene International gets Sebi apporval for IPOAfter surging 2.93 per cent to Rs 460 in intraday trade, shares of Biocon ended at Rs 453.75, up 1.53 per cent on the BSE.
- Biocon's arm Syngene International gets Sebi approval for IPOThe company plans to sell 22 mn equity shares, including reservation of up to two mn shares for Biocon shareholders.
- Biocon surges as company files prospectus for Syngene IPO to raise Rs 600 crore; ends in redBiocon surged over 3% in intraday trade on Thursday after the company filed prospectus for Syngene IPO on Wednesday to raise Rs 600 cr .
- Stocks of QIP candidates more promising than forthcoming IPOsThe QIP activity has taken off very well, says Diwan. Ashoka Buildcon has come to the market at the right time, he adds.
- Planning to list Syngene, selling stake part of IPO process: Kiran Mazumdar Shaw, Biocon'Syngene is India’s leading research services company in discovery and development space, especially in the pharmaceutical sector,' says Ma...
- Biocon eyes $1 bn revenue in next three fiscals: Kiran Mazumdar ShawBiotechnology major Biocon on Tuesday said it aims to achieve revenues of USD 1 billion in the next three years.
- Biocon to sell up to 25% in Syngene via IPOBiocon will launch an IPO for its fully-owned contract research subsidiary Syngene this financial year.
Load More
